Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ...

Vaxcyte (NASDAQ:PCVX – Free Report) had its price target cut by The Goldman Sachs Group from $138.00 to $100.00 in a report ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Get Our Latest Stock Analysis on Vaxcyte Vaxcyte Stock Performance Vaxcyte stock opened at $30.56 on Thursday. Vaxcyte has a 52 week low of $30.01 and a 52 week high of $121.06. The firm has a ...

BofA lowered the firm’s price target on Vaxcyte (PCVX) to $137 from $157 following the company’s report of Phase 2 dose-finding data for VAX-24 ...

Needham lowered the firm’s price target on Vaxcyte (PCVX) to $90 from $140 and keeps a Buy rating on the shares after the company announced ...

March 31, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...

I am incredibly proud of the entire Vaxcyte team for these achievements.” "Despite current vaccination efforts, Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally in ...